CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era

Immunotherapy. 2018 Feb 1;10(4):251-254. doi: 10.2217/imt-2017-0162.
No abstract available

Keywords: CAR-T; chimeric antigen receptor; chronic lymphocytic leukemia; cytokine-release syndrome.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenine / analogs & derivatives
  • Humans
  • Immunotherapy / methods*
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology*
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
  • Piperidines
  • Pyrazoles*
  • Pyrimidines*
  • Receptors, Antigen, T-Cell / immunology
  • Receptors, Antigen, T-Cell / therapeutic use*
  • T-Lymphocytes / immunology*

Substances

  • CD19-specific chimeric antigen receptor
  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • Receptors, Antigen, T-Cell
  • ibrutinib
  • Adenine